• Explore /
  • Poster
  • / Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.

Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.

Abstract Poster

Authors

Ryan Sullivan

Ryan J. Sullivan

Massachusetts General Hospital, Boston, MA

Ryan J. Sullivan , Ke Liu , Jason M. Redman , Nicholas Tschernia , Andrew Bayliffe , Alyssa Marino , Karunya Srinivasan , Madan Katragadda , Jacques Moisan , Rajesh Chopra , Aurelien Marabelle , Howard L. Kaufman , Lillian L. Siu , Zhen Su , James L. Gulley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT05592626

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS2671)

DOI

10.1200/JCO.2023.41.16_suppl.TPS2671

Abstract #

TPS2671

Poster Bd #

509a

Abstract Disclosures

Similar Posters

First Author: Kyle Draheim

Poster

2024 ASCO Annual Meeting

<span>Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.</span>

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

First Author: Jiayong Liu

First Author: Paolo Antonio Ascierto

First Author: Daniel Olson